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Abstract
Objective—To assess long-term outcomes of children with symptomatic congenital 
cytomegalovirus (CMV) disease detected at birth.
Methods—We used Cox regression to assess risk factors for intellectual disability (intelligence 
quotient <70), sensorineural hearing loss (SNHL; hearing level ≥25 dB in any audiometric 
frequency), and vision impairment (best corrected visual acuity >20 or based on ophthalmologist 
report).
Results—Among 76 case-patients followed through median age of 13 (range: 0–27) years, 56 
(74%) had SNHL, 31 (43%, n=72) had intellectual disability, and 18 (27%, n=66) had vision 
impairment; 28 (43%, n=65) had intellectual disability and SNHL with/without vision impairment. 
Microcephaly was significantly associated with each of the three outcomes. Tissue destruction and 
dysplastic growth on head computed tomography scan at birth was significantly associated with 
intellectual disability and SNHL.
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Conclusion—Infants with symptomatic congenital CMV disease may develop moderate to 
severe impairments, which were associated with presence of microcephaly and brain 
abnormalities.
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BACKGROUND
Congenital cytomegalovirus (CMV) infection can cause microcephaly and result in a 
spectrum of neurodevelopmental disorders, such as sensorineural hearing loss (SNHL), 
vision loss, and intellectual impairment.1 In the United States, an estimated 20 000 (0.5%) 
children are born with congenital CMV infection annually2, 3, of whom  approximately 2 
000–3 000 (10–15%) are symptomatic at birth, including 400 (2%) with 
microcephaly.4, 5, 6, 7, 8, 9, 10, 11, 12 About 50–70% of children with symptomatic CMV 
disease at birth develop permanent sequelae.1 Antiviral treatment has been shown to improve 
developmental outcomes and reduce progression of SNHL in children with neurologic 
complications of congenital CMV disease at birth.13, 14 However, because disease symptoms 
at birth may be mild or non-specific, it is likely that only a minority of children with 
symptomatic congenital CMV disease are clinically diagnosed in the absence of newborn 
screening.15 Thus, the full impact of congenital CMV disease throughout the course of 
childhood remains largely unrecognized. Furthermore, the varying definitions of 
symptomatic congenital CMV disease complicates comparisons across studies.16, 17 In the 
present study, we describe neurodevelopmental, hearing, and vision outcomes of children 
with symptomatic congenital CMV disease detected at birth followed through a median age 
of 13 years.
METHODS
Our study included 76 children born during 1983–2005 who were enrolled in the Congenital 
CMV Longitudinal Study11, 18, 19 as case-patients with confirmed symptomatic congenital 
CMV disease, defined as a newborn with CMV infection detected by culture of urine 
samples collected within 3 weeks of life who presented at least one of the following CMV-
related signs at birth: purpura/petechiae, jaundice, hepatosplenomegaly, microcephaly, 
unexplained neurological abnormality, elevated liver enzymes (alanine aminotransferase 
>100 IU), hyperbilirubinemia (total bilirubin >3mg/dl), hemolytic anemia, or 
thrombocytopenia (platelet count <75 000/mm3). We did not consider infants who were 
small for gestational age (SGA) or had congenital SNHL in the absence of at least one of the 
above signs as having symptomatic congenital CMV disease.16 Seventy-three (95%) case-
patients were referrals from several hospitals, and 4 (5%) case-patients were identified by 
routine newborn CMV screening at Women’s Hospital of Texas, Houston TX, where the 
observed CMV birth prevalence was 0.4% (135 CMV-positive infants among 32 543 
screened during 1982–1992)19. Ninety-six (71%) CMV-positive newborns whose parents 
provided consent were enrolled in the Congenital CMV Longitudinal Study, 4 (4%) were 
case-patients included in the present analysis, and 92 (96%) were asymptomatic at birth for 
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whom hearing outcomes have been previously described.19 Case-patients had neuroimaging 
evaluations performed by head computed tomography (CT) scans within 4 months of age, 
and were followed with neurodevelopmental, hearing and ophthalmologic evaluations during 
infancy, pre-school, elementary, middle, and high school years. The Institutional Review 
Board for Human Subject Research for Baylor College of Medicine and Affiliated Hospitals 
approved the study protocol.
We describe case-patients by demographic characteristics, CMV-related signs at birth, and 
other clinical characteristics, including pre-term birth and SGA. We categorized case-
patients as SGA or having microcephaly in two ways - based on physicians’ clinical 
assessment at birth and defining SGA as birth weight ≤10th percentile and microcephaly as 
fronto-occipital head circumference ≤3rd and ≤10th percentiles, using the Olsen’s 
intrauterine growth curves.20 We classified abnormal head CT findings in infancy into three 
broad categories implying 1) tissue destruction (calcification, hemorrhage, stroke, 
encephalomalacia, white matter lucency, porencephaly/cysts, or atrophy); 2) attenuated 
growth (immaturity, hypoplasia, or underopercularization); and 3) dysplastic growth 
(migrational abnormalities, such as lissencephaly or pachygyria). Volume loss was inferred 
by dilatation of cisterns and/or cerebrospinal fluid spaces.
Neurodevelopmental evaluations included assessments of physical, motor, sensory, and 
cognitive development in infants and young children, and measurement of intelligence 
quotient or adaptive level of functioning among older children. Neurodevelopmental 
evaluation was done using one of the following tests: Bayley Scales of Infant Development21 
(n=13), McCarthy Scales of Children’s Abilities22 (n=4), Wechsler Intelligence Scale for 
Children - 3rd edition23 (n=4), Wechsler Abbreviated Scale of Intelligence24 (n=23), 
Kaufman Assessment Battery for Children25 (n=7), Leiter International Performance Scale – 
Revised26 (n=2), Stanford Binet Intelligence Scale27 (n=2), and Vineland Adaptive Behavior 
Scales28 (n=18). All tests have scores standardized to a mean of 100 with a standard 
deviation of 15 or 16, allowing us to combine the scores from case-patients assessed at 
different ages using different instruments. For the 3 case-patients who received the Bayley 
Scales of Infant Development at the last evaluation at ≥42 months of age, we calculated the 
IQ based on the age-equivalent scores divided by the age at the time of testing multiplied by 
100. We categorized case-patients as having intellectual disability, borderline intelligence, 
and normal intelligence when standard scores at last evaluation were <70, 70–84, and ≥85, 
respectively.29
Hearing evaluations included click and tone-burst auditory brainstem response (ABR), 
behavioral audiometry from 0.25 to 8 kHz, and tympanometry. We defined SNHL as ≥25 dB 
hearing level for the click ABR or at any frequency for the corrected tone-burst or pure-tone 
air conduction results, in the absence of middle ear disorder. We categorized SNHL for each 
ear as congenital/early-onset when detected in the first ABR assessment at age ≤12 months 
and confirmed in subsequent assessments, or as delayed-onset when detected after one or 
more assessments with normal hearing. We also categorized SNHL by laterality and severity, 
as previously described.19
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Ophthalmologic evaluations included external ocular exam, indirect ophthalmoscopy, and 
measurement of best corrected visual acuity (Snellen score) in older children or assessment 
of fixation behavior in nonverbal and preverbal children. We defined an ophthalmic 
abnormality as any of the following conditions: chorioretinitis, optic nerve atrophy, 
strabismus (including esotropia or exotropia), nystagmus, amblyopia, or astigmatism. Based 
on the last ophthalmologic visit, we categorized case-patients as having normal vision (≤20), 
mild/moderate vision impairment (21–69), low vision (70–199), and legal blindness (≥200), 
using the Snellen scores in the better eye, or based on the ophthalmologist assessment for 
nonverbal and pre-verbal children.30
Using the Cox proportional hazards regression model and the Firth method to reduce small 
sample size bias31, we calculated hazard ratios (HR) and 95% confidence intervals (CI) to 
assess whether selected clinical signs at birth (petechiae/purpura, jaundice or 
hyperbilirubinemia, hepatosplenomegaly, microcephaly, SGA, or pre-term birth) or 
abnormal head CT findings (tissue destruction, attenuated growth, or dysplastic growth) 
within 4 months of birth were predictors for intellectual disability, SNHL, ophthalmic 
abnormality, or vision impairment. For the models, we defined microcephaly as head 
circumference ≤3rd percentile and SGA as birth weight ≤10th percentile. We did not combine 
clinical signs at birth with head CT findings as predictors in the same model because they 
were potentially correlated with each other. We considered results with a p-value <0.05 as 
statistically significant. For analyses, we used SAS version 9.3 (SAS Institute Inc., Cary, 
NC, USA).
RESULTS
Demographic and clinical characteristics at birth
Of the 76 case-patients, 55 (72%) were born during 1983–1998, before establishment of the 
Texas Newborn Hearing Screening Program in 1999, and 21 (28%) during 1999–2005. The 
majority of case-patients were born to mothers who were <25 years of age (62%), non-
Hispanic White (57%), married (60%), primipara (52%) and who had no other living 
children at the time of birth (59%).
Thirty-five (46%) case-patients were males and 52 (68%) were born at term. Fifty-nine 
(78%) case-patients had urine samples for CMV testing collected within 3 days of life, and 
17 (22%) between 4–21 days of life. The most common CMV-related signs present at birth 
were petechiae/purpura (72%) and thrombocytopenia (70%) (Table 1). A greater proportion 
of case-patients were SGA based on the Olsen’s intrauterine growth curves than based on 
physician’s clinical assessment at birth (58% vs. 37%). The proportion of case-patients with 
microcephaly was 41%, based on physician’s clinical assessment at birth. Among 73 case-
patients with head circumference measurement recorded, 34% had head circumference ≤3rd 
and 51% ≤10th percentile for gestational age. The median age at last follow-up visit was 13 
(range: 0–27) years. Eight case-patients died during the follow-up period; 1 (1.3%) at age 2 
months, 2 (2.6%) at 2 years, 3 (3.8%) at 12–13 years, and 2 (2.6%) at 20 years. One case-
patient who died had a diagnosis of sudden infant death syndrome, 4 had respiratory failure 
(1 at age 2 years and 3 at ages 12–13 years), 2 had post-surgical complications (ages 2 and 
20 years), and 1 had an accidental drug overdose (age 20 years).
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Head computed tomography scan findings
Seventy-three case-patients had a head CT performed within the first 4 months of life, at a 
median age of 8 days (range 0–4 months). A total of 62 (85%) case-patients had abnormal 
findings, categorized as tissue destruction in 49 (67%), attenuated growth in 21 (29%), and 
dysplastic growth in 6 (8%) (Table 1). The most common abnormal findings were 
intracranial calcifications, ventricular dilatation, and white matter lucency, observed in 43 
(59%), 40 (55%), and 20 (27%) case-patients, respectively. Volume loss was observed in 34 
(69%) case-patients with tissue destruction, in 12 (57%) with growth attenuation, and in 5 
(83%) with dysplastic growth. In univariate analyses, microcephaly at birth was significantly 
associated with tissue destruction and dysplastic growth shown by head CT; pre-term birth 
was significantly associated with attenuated growth shown by head CT (p<0.05).
Neurodevelopmental, hearing and vision outcomes
Among 72 case-patients with a neurodevelopmental evaluation, the median age at the last 
evaluation was 10 (range: 0.4–27) years. Thirty-one (43%) case-patients had intellectual 
disability, 12 (17%) had borderline intelligence, and 29 (40%) had normal intelligence 
(Table 1). Among 31 case-patients with intellectual disability, the median intelligence score 
was 35 (range: 5–67) and the median verbal score was 33 (range: 20–74). Among 12 case-
patients with borderline intelligence, the median intelligence score was 82 (range: 70–84), 
and the median verbal score was 78 (range: 72–97). Of 29 case-patients with normal 
intelligence, the median intelligence score was 106 (range: 85–122), and the median verbal 
score was 105 (range: 84–120).
Among 76 case-patients with an audiologic evaluation, the median age at first evaluation 
was 18 days (range: 4 days–8 years); 75 case-patients were first evaluated within 10 months 
of birth. Overall, 56 (74%) case-patients had SNHL (Table 1), among whom 44 (79%) had 
congenital/early-onset SNHL and 12 (21%) developed delayed-onset SNHL detected at a 
median age of 3 (range: 0.5–11) years. Forty-seven (84%) case-patients with SNHL had 
bilateral loss, of which 38 (81%) had bilateral loss at first diagnosis, and 9 (19%) were 
initially diagnosed with unilateral loss, but developed delayed-onset SNHL in the contra-
lateral ear. The median interval from unilateral to bilateral loss was 3 months (range: 7 days–
5 years) among 5 case-patients who initially presented with unilateral congenital/early-onset 
SNHL, and 4 years (range: 3–6 years) among 4 case-patients who presented with unilateral 
delayed-onset SNHL.
Most case-patients with SNHL had moderate to profound SNHL since infancy and SNHL 
severity worsened with age. At first assessment, 44% of all case-patients with SNHL and 
32% of those with bilateral SNHL had profound loss in the poorer- and better-hearing ears, 
respectively. At last assessment, 61% of all case-patients with SNHL and 57% of those with 
bilateral SNHL had profound loss in the poorer- and better-hearing ears. Thirty-five (63%) 
of 56 case-patients with SNHL received hearing aids, among whom 26 (74%) received 
bilateral hearing aids. A total of 15 (27%) case-patients received cochlear implants, 
including 10 who initially used hearing aids. Five (33%) received the first cochlear implant 
by age 2 years, 6 (40%) between 3–7 years, and 4 (27%) at ≥14 years. Five case-patients 
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received cochlear implants bilaterally, among whom the second implantation was done at a 
median of 2 (range: 1–5) years after the first.
Among 76 case-patients, 39 (51%) had an ophthalmic abnormality, including 19 (25%) with 
chorioretinitis and 9 (12%) with optic nerve atrophy (Table 1). Overall, among 66 (87%) 
case-patients with vision evaluation, 44 (67%) had normal vision, 8 (12%) had mild/
moderate vision impairment, 4 (6%) had low vision, and 10 (15%) had legal blindness. 
Among 41 (54%) case-patients with a Snellen score for both eyes, including 12 (29%) with 
correction, 32 (78%) had normal vision, 8 (20%) had mild/moderate vision impairment, and 
1 (2%) had low vision. Among 25 (33%) case-patients without a Snellen score in both eyes, 
12 (48%) had normal vision, 3 (12%) had low vision, and 10 (40%) had legal blindness.
Overall, among 65 (86%) case-patients with neurodevelopmental, hearing and vision 
evaluations, 28 (43%) had intellectual disability and SNHL with or without vision 
impairment, 2 (3%) had intellectual disability with normal hearing and vision, and 16 (25%) 
had borderline/normal intelligence with moderate to profound SNHL in the better-hearing 
ear (1 of whom had legal blindness, and 2 with mild/moderate vision impairment). The 
remaining 19 (29%) case-patients had borderline/normal intelligence, of whom 7 had 
moderate to profound SNHL in the poorer-hearing ear, 2 had mild/moderate vision 
impairment, and 10 had normal hearing and vision.
Predictors of intellectual disability, SNHL, ophthalmic abnormalities, and vision 
impairment
In multivariate analysis of clinical signs at birth, microcephaly was significantly associated 
with intellectual disability (HR: 3.4, 95% CI: 1.5–7.6), SNHL (HR: 2.6, 95% CI: 1.4–5.0), 
ophthalmic abnormality (HR: 2.7, 95% CI: 1.2–6.0), and vision impairment (HR: 6.4, 95% 
CI: 1.6–26.4) (Table 2). Petechiae/purpura were associated with decreased risk of SNHL 
(HR: 0.4, 95% CI: 0.2–0.8), while hepatosplenomegaly was associated with increased risk of 
SNHL (HR: 3.4, 95% CI: 1.6–7.3). Jaundice was associated with a decreased risk of vision 
impairment (HR: 0.2, 95% CI: 0.1–0.8). In multivariate analyses of head CT findings, tissue 
destruction was significantly associated with intellectual disability (HR: 4.2, 95% CI: 1.1–
16.1) and SNHL (HR: 2.2, 95% CI: 1.1–4.3). Dysplastic growth was significantly associated 
with intellectual disability (HR: 4.4, 95% CI: 1.7–11.5), SNHL (HR: 2.4, 95% CI: 1.0–5.8), 
ophthalmic abnormalities (HR: 6.1, 95% CI: 2.3–16.6), and vision impairment (HR: 10.4, 
95% CI: 2.9–37.7). Neither pre-term birth nor attenuated growth shown by head CT were 
significantly associated with intellectual disability, SNHL, ophthalmic abnormalities or 
vision impairment (p>0.05).
DISCUSSION
In this longitudinal study of children with confirmed symptomatic congenital CMV disease, 
the majority of whom were clinically referred, we observed a high proportion of case-
patients with microcephaly, intellectual disability, SNHL, ophthalmic abnormalities and 
vision impairment. Among case-patients with intellectual disability, the median intelligence 
score was in the severe to profound range, suggesting that a substantial proportion of these 
children likely require daily supervision, help with self-care activities, and special education, 
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in addition to long-term monitoring and health interventions. It is likely that a greater 
proportion of children with symptomatic congenital CMV disease identified through 
referrals have more severe manifestations at birth and disabilities than those who would be 
identified through newborn screening.32 Thus, our data should not be generalized to all 
infants with congenital CMV infection, among whom only 10–15% present with 
symptomatic disease of varying degree of severity at birth. We found the prevalence of 
moderate to severe outcomes was 71% among our case-patients in contrast to the 32% found 
among infants with congenital CMV infection identified in 2 large population-based 
newborn screening studies.33 We did not include congenital SNHL as a defining condition 
for symptomatic congenital CMV disease which if we had would have resulted in a greater 
number of infants classified as having symptomatic infection and a lower estimate of the 
proportion with intellectual disability.
We found microcephaly was significantly associated with abnormal head CT findings 
indicative of tissue destruction and dysplastic growth, as well as intellectual disability, 
SNHL, ophthalmic abnormalities and vision impairment. Our findings expand on a previous 
analysis of 41 case-patients from our cohort, reinforcing the specificity of microcephaly as a 
predictor of poor cognitive outcome.34 None of the case-patients in our study with normal 
intelligence, hearing, and vision had microcephaly at birth. In newborn screening studies, the 
proportion of children with symptomatic congenital CMV disease who have microcephaly 
ranges between 7–40%.4, 5, 6, 7, 8, 9, 10, 11, 12 Many of these studies used the 10th percentile 
as a cutoff for microcephaly, hence, the prevalence of microcephaly may have been 
overestimated. In our study, using the 3rd percentile for head circumference adjusted for 
gestational age at birth, we found 34% of case-patients had microcephaly, lower than the 
40% classified by physician report. Using standardized methods to assess microcephaly in 
infants with congenital CMV infection is important, not only to allow comparability across 
studies, but to accurately inform clinical management decisions and inform prognosis.
Although head CT abnormalities have been associated with impairments/disabilities in 
children with symptomatic congenital CMV disease, the types of abnormalities that predict 
adverse outcomes have not been assessed.35 We found that tissue destruction and dysplastic 
growth were significantly associated with microcephaly at birth, intellectual disability and 
SNHL. Dysplastic growth was also associated with ophthalmic abnormalities and vision 
impairment. Currently, it is recommended that CT be limited to selected cases because 
exposure to ionizing radiation may affect the developing human brain. More recently, 
neuroimaging using magnetic resonance, which was not available for our cohort, and 
ultrasound, have been recommended for the diagnosis and categorization of brain 
developmental disorders and white matter disease, including for children with asymptomatic 
congenital CMV infection.36, 37, 38 Severe brain abnormalities very similar to those of our 
case-patients with symptomatic congenital CMV disease have been recently reported in 
cases of microcephaly associated with congenital Zika virus infection.39 Development of 
standard clinical and diagnostic protocols, including neuroimaging evaluations, would be 
needed should newborn screening for congenital CMV infection be implemented. Our 
findings from head CT suggest that tissue destruction or dysplastic growth shown by 
magnetic resonance or ultrasound would be useful to inform prognosis of affected children.
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In our study, the majority of case-patients had moderate to profound SNHL since early 
infancy and received hearing device interventions, including hearing aids and cochlear 
implants. The first cochlear implantation among our case-patients was performed in 1998. 
Twice as many children who received cochlear implants in our study would likely have met 
the current candidacy criteria for cochlear implantation. Data from small studies have shown 
that children with congenital CMV-related SNHL may benefit from cochlear implantation 
but perform less well than a comparable group of children with implants who do not have 
congenital CMV infection; this lag may be related to the degree of CMV-related motor or 
cognitive disabilities.40, 41, 42, 43 Children who receive cochlear implants require ongoing 
audiological and otolaryngological follow-up, as well as training/rehabilitation to develop a 
wide range of listening skills for optimal benefit from their devices.44 More data on quality 
of life, language skills and educational achievement following cochlear implantation in 
children with congenital CMV-related SNHL will be useful to document potential benefits 
and provide realistic expectations to patients and parents considering this intervention.
Vision impairment in children with symptomatic congenital CMV disease may be caused by 
cortical, optic nerve, and/or retinal abnormalities.45 Data on long-term vision outcomes for 
children with congenital CMV infection are limited.1 Overall, 21% of our case-patients had 
low vision or legal blindness. In our study, half of case-patients had an ophthalmic 
abnormality; 25% had chorioretinitis, not much higher than in previous reports.32 Among 
case-patients with vision evaluation, 55% of those with chorioretinitis and/or optic nerve 
atrophy had at least mild/moderate vision impairment, consistent with the 58% reported in 
another study.46 The evidence suggests that infants with symptomatic congenital CMV 
disease should receive careful ophthalmologic screening and regular follow-up examinations 
to allow for early intervention.45, 47
Our study had some limitations. Clinical data for CMV-positive newborns that were 
identified by routine CMV screening but not enrolled in the study were not available. 
Although we estimate only 2–3 of these newborns would have presented with symptomatic 
disease at birth, those who died in the neonatal period would not have had the opportunity to 
be enrolled in the study. In our cohort, the cumulative mortality rate within 2 years of life 
was 4%, comparable to that of 5–6% reported in previous studies.1, 32 Although a few case-
patients were born pre-term, we found no significant association of pre-term birth or head 
CT findings suggesting prematurity with any of the severe outcomes. Because case-patients 
were born over the course of 2 decades, the available diagnostic procedures, treatment and 
interventions evolved over time. We did not investigate all clinically important outcomes, 
including outcomes such as cerebral palsy and nutritional status, or interventions that these 
children required or received, such as orthopedic surgeries, assistive devices, and physical, 
occupational, speech and language therapies. Additionally, we were unable to report on the 
impact on quality of life of affected children and families, which should be included for 
more complete assessment of burden of disease and its economic impact.
Determining the burden of disease associated with congenital CMV infection is critical to 
assess the cost-effectiveness of newborn screening for congenital CMV infection. The 
severity of outcomes vary widely and the data available on the range of disabilities among 
affected children are limited.16, 48, 49 Our study provides detailed outcome data for a subset 
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of congenitally infected infants that were diagnosed at birth and likely overestimates the 
burden of disease among all children with congenital CMV infection that is symptomatic at 
birth. More data on the prevalence and spectrum of long-term outcomes among both 
symptomatic and asymptomatic infants are needed to estimate the potential benefit and 
assess the cost-effectiveness of newborn screening for congenital CMV infection.
In the United States, symptomatic congenital CMV disease is estimated to affect 
approximately 2 000–3 000 newborns annually. An additional 900 infants with 
asymptomatic congenital CMV infection are estimated to have SNHL within 8 weeks of life, 
although nearly half of these infants are likely missed by newborn hearing screening.50 
Children with delayed-onset SNHL occurring during the first 9 months of age are likely to 
benefit from early intervention.16 By age 5 years, 360 (2%) of children with asymptomatic 
congenital CMV infection are estimated to have severe enough bilateral SNHL to potentially 
meet candidacy criteria for cochlear implantation.19 A laboratory-confirmed diagnosis of 
congenital CMV disease in the first month of life is critical for implementing appropriate 
clinical management, including administration of antivirals for eligible infants.13, 14 Most 
cases of symptomatic congenital CMV disease likely remain undiagnosed because they 
present with mild or non-specific signs.15, 51 Although congenital CMV infection meets 
some of the criteria for inclusion in the newborn screening panel, more research is needed to 
develop a screening test appropriate for large scale implementation, inform guidelines for 
treating and monitoring children with congenital CMV infection, and assess the cost-benefit 
or cost-effectiveness of CMV screening.52, 53
Acknowledgments
We thank all the children who participated in the study, their families and physicians for their lifetime of dedication 
and support for this study, Kim Van Naarden Braun for careful review of the manuscript.
The Congenital CMV Longitudinal Study Group through the years has included: Shahzad Ahmed, Hanna Baer, 
MD, Amit R. Bhatt, MD, Peggy Blum, AuD and Texas Children’s Hospital Audiology, Frank Brown, MD, Francis 
Catlin, MD, Alison C. Caviness, MD, PhD, MPH, David K. Coats, MD, Jane C. Edmonds, MD, Marily Flores, MS, 
Daniel Franklin, MD, Cindy Gandaria, Jewel Greer, Carol Griesser, RN, Mohamed A. Hussein, MD, Isabella 
Iovino, PhD, Allison Istas, MPH, Haoxing (Douglas) Jin, Mary K. Kelinske, OD, Joseph T. Klingen, Antone 
Laurente, PhD, Thomas Littman, PhD, Mary Murphy, MS, Jerry Miller, PhD, Christopher Nelson, MD, Daniel 
Noyola, MD, Evelyn A. Paysse, MD, Alan Percy, MD, Sara Reis, RN, Ann Reynolds, MD, Judith Rozelle, MS, 
O’Brien Smith, PhD, Paul Steinkuller, MD, Marie Turcich, MS, Sherry Sellers Vinson, MD, Robert G. Voigt, MD, 
Bethann Walmus, Jill Williams, MA, Daniel Williamson, MD, Kimberly G. Yen, MD, Martha D. Yow, MD, and 
Gail J. Demmler-Harrison MD.
Funding Sources: The study was supported, in part, by the CMV Research Fund Donors at Baylor College of 
Medicine; the Woman’s Hospital of Texas Research Foundation; the Office of Research Resources and the General 
Clinical Research Center for Children at Texas Children’s Hospital and Baylor College of Medicine (NIH 5M0I 
RR00188-33); the Mental Retardation Research Center at Baylor College of Medicine (NIH-CHHD 5 P30 
HD24064P); the Research to Prevent Blindness, Inc. New York, NY; the Deafness Foundation, Houston, TX; the 
Vale Ashe Foundation, Houston, TX; the Maddie’s Mission Foundation, Katy, TX; the Naymola Foundation, 
Beaumont, TX; the American Pediatric Society-Society for Pediatric Research Summer Student Research Program 
(NIH-CHHD); and the Centers for Disease Control and Prevention (Cooperative Agreement FOA IP 10-006).
Contributor’s Statement
Tatiana M. Lanzieri conceptualized and conducted analysis contained in this report, 
interpreted the data, led the writing of the initial manuscript and revised versions, and 
approved the final version.
Lanzieri et al. Page 9













Jessica Leung conducted analysis contained in this report, interpreted the data, revised the 
manuscript and approved the final version.
Winnie Chung conceptualized the analysis contained in this report, reviewed and interpreted 
individual audiological data, revised the manuscript and approved the final version.
Marily Flores and Jerry A. Miller assisted with data management and quality control for the 
Longitudinal Congenital CMV Study, revised the manuscript and approved the final version.
Peggy Blum conceptualized and provided audiological follow-up in the Longitudinal 
Congenital CMV Study, revised the manuscript and approved the final version.
A. Chantal Caviness was the co-Principal Investigator for the Longitudinal Congenital CMV 
Study, revised individual clinical, laboratory and head computed tomography data, 
conducted analysis contained in this report, revised the manuscript and approved the final 
version.
Stephanie R. Bialek conceptualized the analysis contained in this report, interpreted the data, 
revised the manuscript and approved the final version.
Sherry S. Vinson, Marie R. Turcich, and Robert G. Voigt conducted the neurodevelopmental 
evaluations, revised the manuscript and approved the final version.
Gail Demmler-Harrison was the Principal Investigator for the Longitudinal Congenital CMV 
Study, provided patient follow-up, conceptualized the analysis contained in this report, 
interpreted the data, revised the manuscript and approved the final version.
Abbreviations





SGA small for gestational age
SNHL sensorineural hearing loss
References
1. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory 
sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007; 
17(5):355–363. [PubMed: 17542052] 
2. Boppana SB, Ross SA, Shimamura M, Palmer AL, Ahmed A, Michaels MG, et al. Saliva 
polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med. 2011; 
364(22):2111–2118. [PubMed: 21631323] 
Lanzieri et al. Page 10













3. Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL, et al. Dried blood spot 
real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus 
infection. JAMA. 2010; 303(14):1375–1382. [PubMed: 20388893] 
4. Ahlfors K, Ivarsson SA, Harris S. Report on a long-term study of maternal and congenital 
cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. 
Scand J Infect Dis. 1999; 31(5):443–457. [PubMed: 10576123] 
5. Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Symptomatic congenital cytomegalovirus 
infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics. 1999; 
104(1 Pt 1):55–60. [PubMed: 10390260] 
6. Melish ME, Hanshaw JB. Congenital cytomegalovirus infection. Developmental progress of infants 
detected by routine screening. Am J Dis Child. 1973; 126(2):190–194. [PubMed: 4125051] 
7. Numazaki K, Fujikawa T. Chronological changes of incidence and prognosis of children with 
asymptomatic congenital cytomegalovirus infection in Sapporo, Japan. BMC Infect Dis. 2004; 4:22. 
[PubMed: 15236662] 
8. Peckham CS, Chin KS, Coleman JC, Henderson K, Hurley R, Preece PM. Cytomegalovirus 
infection in pregnancy: preliminary findings from a prospective study. Lancet. 1983; 1(8338):1352–
1355. [PubMed: 6134135] 
9. Saigal S, Lunyk O, Larke RP, Chernesky MA. The outcome in children with congenital 
cytomegalovirus infection. A longitudinal follow-up study. Am J Dis Child. 1982; 136(10):896–901. 
[PubMed: 6181675] 
10. Starr JG, Bart RD Jr, Gold E. Inapparent congenital cytomegalovirus infection. Clinical and 
epidemiologic characteristics in early infancy. N Engl J Med. 1970; 282(19):1075–1078. 
[PubMed: 4314607] 
11. Yow MD, Williamson DW, Leeds LJ, Thompson P, Woodward RM, Walmus BF, et al. 
Epidemiologic characteristics of cytomegalovirus infection in mothers and their infants. Am J 
Obstet Gynecol. 1988; 158(5):1189–1195. [PubMed: 2835906] 
12. Koyano S, Inoue N, Oka A, Moriuchi H, Asano K, Ito Y, et al. Screening for congenital 
cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and 
outcomes from a multicentre study. BMJ Open. 2011; 1(1):e000118.
13. Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. 
Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015; 372(10):
933–943. [PubMed: 25738669] 
14. Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Effect of 
ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the 
central nervous system: a randomized, controlled trial. J Pediatr. 2003; 143(1):16–25. [PubMed: 
12915819] 
15. Lanzieri TM, Bialek SR, Bennett MV, Gould JB. Cytomegalovirus infection among infants in 
California neonatal intensive care units, 2005–2010. J Perinat Med. 2014; 42(3):393–399. 
[PubMed: 24334425] 
16. Cannon MJ, Griffiths PD, Aston V, Rawlinson WD. Universal newborn screening for congenital 
CMV infection: what is the evidence of potential benefit? Rev Med Virol. 2014; 24(5):291–307. 
[PubMed: 24760655] 
17. Lanzieri TM, Dollard SC, Bialek SR, Grosse SD. Systematic review of the birth prevalence of 
congenital cytomegalovirus infection in developing countries. Int J Infect Dis. 2014; 22:44–48. 
[PubMed: 24631522] 
18. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with 
asymptomatic congenital cytomegalovirus infection. Pediatrics. 1992; 90(6):862–866. [PubMed: 
1331946] 
19. Lanzieri TM, Chung W, Flores M, Blum P, Caviness AC, Bialek SR, et al. Hearing loss in children 
with asymptomatic congenital cytomegalovirus infection. Pediatrics. 2017
20. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based 
on United States data. Pediatrics. 2010; 125(2):e214–224. [PubMed: 20100760] 
21. Bayley, N. Bayley Scales of Infant Development. San Antonio, TX: Psychological Corporation; 
1969. 
Lanzieri et al. Page 11













22. McCarthy, D. McCarthy Scale of Children’s Abilities. Psychological Corp; New York: 1972. 
23. Wechsler, D. Wechsler Intelligence Scale for Children. 3. The Psychological Corporation; San 
Antonio, TX: 1991. 
24. Wechsler, D. Wechsler Abbreviated Scale of Intelligence. The Psychological Corporation; San 
Antonio, TX, USA: 1999. 
25. Kaufman, AS., Kaufman, NL. Kaufman Assessment Battery for Children. Circle Pines, MN: 
American Guidance Service; 1983. 
26. Roid, G., Miller, L. Leiter International Performance Scale-Revised: Examiner’s Manual. Wood 
Dale, IL: Stoelting Co; 1997. 
27. Thorndike, RHE., Sattler, J. The Stanford-Binet intelligence scale fourth edition Guide for 
administering and scoring. Riverside Pub. Co; Chicago, IL: 1986. p. 192
28. Sparrow, SS., Balla, DA., Cicchetti, DV. Vineland Adaptive Behavior Scales—Interview Edition 
Survey Form. American Guidance Service; Circle Pines, MN: 1984. 
29. Sampath V, Bowen J, Gibson F. Risk factors for adverse neurodevelopment in extremely low birth 
weight infants with normal neonatal cranial ultrasound. J Perinatol. 2005; 25(3):210–215. 
[PubMed: 15578032] 
30. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and 
Prevention. Metropolitan Atlanta Developmental Disabilities Surveillance Program (MADDSP) 
Case Definitions. [cited September 30th, 2016.]Available from: http://www.cdc.gov/ncbddd/
developmentaldisabilities/casedefinitions.html#vision
31. King G, Zeng L. Logistic Regression in Rare Events Data. Political Analysis. 2001; 9:137–163.
32. Dreher AM, Arora N, Fowler KB, Novak Z, Britt WJ, Boppana SB, et al. Spectrum of disease and 
outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr. 2014; 
164(4):855–859. [PubMed: 24433826] 
33. Townsend CL, Forsgren M, Ahlfors K, Ivarsson SA, Tookey PA, Peckham CS. Long-term 
outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect 
Dis. 2013; 56(9):1232–1239. [PubMed: 23334811] 
34. Noyola DE, Demmler GJ, Nelson CT, Griesser C, Williamson WD, Atkins JT, et al. Early 
predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J 
Pediatr. 2001; 138(3):325–331. [PubMed: 11241037] 
35. Boppana SB, Fowler KB, Vaid Y, Hedlund G, Stagno S, Britt WJ, et al. Neuroradiographic findings 
in the newborn period and long-term outcome in children with symptomatic congenital 
cytomegalovirus infection. Pediatrics. 1997; 99(3):409–414. [PubMed: 9041297] 
36. Alarcon A, Martinez-Biarge M, Cabanas F, Quero J, Garcia-Alix A. A Prognostic Neonatal 
Neuroimaging Scale for Symptomatic Congenital Cytomegalovirus Infection. Neonatology. 2016; 
110(4):277–285. [PubMed: 27344149] 
37. van der Knaap MS, Vermeulen G, Barkhof F, Hart AA, Loeber JG, Weel JF. Pattern of white matter 
abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link 
pattern with congenital cytomegalovirus infection. Radiology. 2004; 230(2):529–536. [PubMed: 
14752192] 
38. Lanari M, Capretti MG, Lazzarotto T, Gabrielli L, Rizzollo S, Mostert M, et al. Neuroimaging in 
CMV congenital infected neonates: how and when. Early Hum Dev. 2012; 88(Suppl 2):S3–5.
39. Hazin AN, Poretti A, Di Cavalcanti Souza Cruz D, Tenorio M, van der Linden A, Pena LJ, et al. 
Computed Tomographic Findings in Microcephaly Associated with Zika Virus. New England 
Journal of Medicine. 2016; 374(22):2193–2195.
40. Malik V, Bruce IA, Broomfield SJ, Henderson L, Green KM, Ramsden RT. Outcome of cochlear 
implantation in asymptomatic congenital cytomegalovirus deafened children. Laryngoscope. 2011; 
121(8):1780–1784. [PubMed: 21792969] 
41. Viccaro M, Filipo R, Bosco E, Nicastri M, Mancini P. Long-term follow-up of implanted children 
with cytomegalovirus-related deafness. Audiol Neurootol. 2012; 17(6):395–399. [PubMed: 
22922606] 
42. Ciorba A, Bovo R, Trevisi P, Bianchini C, Arboretti R, Martini A. Rehabilitation and outcome of 
severe profound deafness in a group of 16 infants affected by congenital cytomegalovirus 
infection. Eur Arch Otorhinolaryngol. 2009; 266(10):1539–1546. [PubMed: 19283400] 
Lanzieri et al. Page 12













43. Matsui T, Ogawa H, Yamada N, Baba Y, Suzuki Y, Nomoto M, et al. Outcome of cochlear 
implantation in children with congenital cytomegalovirus infection or GJB2 mutation. Acta 
Otolaryngol. 2012; 132(6):597–602. [PubMed: 22364789] 
44. American Academy of Audiology. Cochlear Implants in Children. 
45. Ghekiere S, Allegaert K, Cossey V, Van Ranst M, Cassiman C, Casteels I. Ophthalmological 
findings in congenital cytomegalovirus infection: when to screen, when to treat? J Pediatr 
Ophthalmol Strabismus. 2012; 49(5):274–282. [PubMed: 22800795] 
46. Anderson KS, Amos CS, Boppana S, Pass R. Ocular abnormalities in congenital cytomegalovirus 
infection. J Am Optom Assoc. 1996; 67(5):273–278. [PubMed: 8888845] 
47. Coats DK, Demmler GJ, Paysse EA, Du LT, Libby C. Ophthalmologic findings in children with 
congenital cytomegalovirus infection. J AAPOS. 2000; 4(2):110–116. [PubMed: 10773810] 
48. Gantt S, Dionne F, Kozak FK, Goshen O, Goldfarb DM, Park AH, et al. Cost-effectiveness of 
Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection. JAMA 
Pediatr. 2016; 170(12):1173–1180. [PubMed: 27723885] 
49. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of 
permanent bilateral hearing loss: a quantitative assessment. J Clin Virol. 2008; 41(2):57–62. 
[PubMed: 17959414] 
50. Fowler KB, McCollister FP, Sabo DL, Shoup AG, Owen KE, Woodruff JL, et al. A Targeted 
Approach for Congenital Cytomegalovirus Screening Within Newborn Hearing Screening. 
Pediatrics. 2017
51. Townsend CL, Peckham CS, Tookey PA. Surveillance of congenital cytomegalovirus in the UK 
and Ireland. Arch Dis Child Fetal Neonatal Ed. 2011; 96(6):F398–403. [PubMed: 21289013] 
52. Grosse SD, Dollard S, Ross DS, Cannon M. Newborn screening for congenital cytomegalovirus: 
Options for hospital-based and public health programs. J Clin Virol. 2009; 46(Suppl 4):S32–36. 
[PubMed: 19783205] 
53. Dollard SC, Schleiss MR, Grosse SD. Public health and laboratory considerations regarding 
newborn screening for congenital cytomegalovirus. J Inherit Metab Dis. 2010; 33(Suppl 2):S249–
254.
Lanzieri et al. Page 13

























Lanzieri et al. Page 14
Table 1
Clinical characteristics at birth, head CT findings and long-term neurodevelopmental, hearing, and vision 
outcomes among children with symptomatic congenital CMV disease (n=76)
Characteristic n (%)
Clinical signs during neonatal period
 Petechiae/purpura 55 (72)
 Jaundice 30 (39)
 Hepatosplenomegaly 38 (50)
 Seizures 5 (7)
 Small for gestational age
 Physician clinical assessment at birth 28 (37)
 Birth weight <10th percentile* 44 (58)
 Microcephaly
 Physician clinical assessment at birth 31 (41)
 Head circumference ≤3rd percentile* (n=73) 25 (34)
 Head circumference ≤10th percentile* (n=73) 37 (51)
Laboratory abnormalities
 Elevated alanine transaminase (>100 IU) (n=70) 12 (17)
 Thrombocytopenia (Platelet count <75,000/mm3) (n=71) 50 (70)
 Hyperbilirubinemia (Total bilirubin > 3mg/dl) (n=74) 28 (38)
 Hemolytic anemia 3 (4)
Head CT findings (n=73)
 Intracranial calcifications 43 (59)
 Ventricular dilatation 40 (55)
 White matter lucency 20 (27)
 Any abnormal finding 62 (85)
 Broad categories
 Tissue destruction 49 (67)
 Attenuated growth 21 (29)
 Dysplastic growth 6 (8)
Neurodevelopmental outcomes (n=72)
 Intellectual disability 31 (43)
 Borderline intelligence 12 (17)
 Normal intelligence 29 (40)
Hearing outcomes
 SNHL 56 (74)
 Normal hearing 20 (26)
 SNHL onset (n=56)
 Congenital/early-onset SNHL 44 (79)
 Delayed-onset SNHL 12 (21)
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Characteristic n (%)
 Laterality (n=56)
 Bilateral SNHL 47 (84)
 Unilateral SNHL 9 (16)
 Severity (n=47) **
 ≥ 25 dB in isolated frequency 1 (2)
 Slight (16 – 25 dB) 5 (11)
 Mild (26 – 40 dB) 2 (4)
 Moderate (41 – 55 dB) 4 (9)
 Moderately severe (56 – 70 dB) 1 (2)
 Severe (71 – 90 dB) 7 (15)
 Profound (>90 dB) 27 (57)
Ophthalmic abnormalities
 Astigmatism 22 (29)
 Strabismus 19 (25)
 Nystagmus 11 (14)
 Amblyopia 3 (4)
 Chorioretinitis 19 (25)
 Optic nerve atrophy 9 (12)
 Any ophthalmic abnormality 39 (51)
Vision outcomes (n=66)
 Normal vision 44 (67)
 Mild/moderate vision impairment 8 (12)
 Low vision 4 (6)
 Legal blindness 10 (15)
*
Based on Olsen’s intrauterine growth charts
**
Better-hearing ear at the last assessment
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